23.6.2020 13:43:53 CEST | ViroGates | Company Announcement

Company Announcement No. 15 - 23 June 2020

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that it has received official notice from Hospital General Universitario Santa Lucía in Cartagena, Spain that the hospital will implement suPARnostic® TurbiLatex on its Roche cobas platform to help the process of triage in the emergency department including also triage in relation to COVID-19 disease.

This is the second hospital in Spain that adopts the suPARnostic® TurbiLatex product in clinical routine use following ViroGates’ previous announcement on 14. February 2020 that the University Hospital in León implemented the product.

The Cartagena University Hospital is a 667 bed hospital located in the Murcia Region in the southeast of Spain. The Hospital serves as a reference hospital in the Region and has an uptake population of approx. 300,000 people.

The implementation at the Hospital has been led by Dra. María Dolores Albaladejo Otón (Head of the Clinical Analysis Service) and Dr. Luis García de Guadiana Romualdo (Doctor Specialist in the Clinical Analysis Area).

Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We are happy to see that yet another clinical customer in Spain appreciate how our suPARnostic® TurbiLatex product can add value in the triage process. We have all gone through a difficult time during the first months of the Corona virus outbreak, but the determination of our collaborators at the Hospital, has resulted in a very valuable tool now being available in the triage process. This is also a result of the tremendous dedication of our Spanish colleagues, that have done everything they could to help our customers making the required tasks, to implement the technology at the Hospital. We look forward to a long-term collaboration with the people in the Hospital to support their triage of acute medical patients.”

Dra. María Dolores Albaladejo says in a comment: “We are very happy to have this new biomarker that has proven to be a useful tool in the Emergency Department for making decisions about the need for hospital admission or discharge. We hope that the first results demonstrating its usefulness in patients with COVID 19 can be confirmed soon in our hospital.”

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

Disclaimer

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20200623-ViroGates Company announcement 15.pdf